GeoVax Labs Inc (GOVX)

Currency in USD
0.7449
-0.0202(-2.64%)
Real-time Data·
GOVX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
GOVX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.73000.7700
52 wk Range
0.430011.1800
Key Statistics
Prev. Close
0.7651
Open
0.77
Day's Range
0.73-0.77
52 wk Range
0.43-11.18
Volume
463.52K
Average Volume (3m)
1.58M
1-Year Change
-63.74%
Book Value / Share
0.57
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GOVX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
10.3750
Upside
+1,292.80%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

GeoVax Labs Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

GeoVax Labs Inc Company Profile

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

GeoVax Labs Inc Earnings Call Summary for Q2/2025

  • GeoVax Labs Q2 2025: Six-month revenue up to $2.5M from $301K YoY; stock down 6.33% to $0.79, recovered 1.9% after hours
  • Net loss of $10.7M ($0.79/share), slight improvement from $10.9M loss in 2024; R&D expenses up 16% to $10M
  • Focus on smallpox and COVID-19 vaccines for immunocompromised, and Gideptin cancer therapy; raised $6M post-quarter
  • CEO David Dodd emphasized improving lives through cancer therapies and vaccines; Gideptin potential for multiple solid tumors
  • Challenges: BARDA contract termination, continued net losses, market volatility, and regulatory hurdles in product development
Last Updated: 28/07/2025, 22:30
Read Full Transcript

Compare GOVX to Peers and Sector

Metrics to compare
GOVX
Peers
Sector
Relationship
P/E Ratio
−0.8x−1.3x−0.5x
PEG Ratio
−0.01−0.010.00
Price/Book
2.4x0.9x2.6x
Price / LTM Sales
3.4x9.6x3.3x
Upside (Analyst Target)
-413.2%42.4%
Fair Value Upside
Unlock47.4%7.2%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 10.3750
(+1,292.80% Upside)

Earnings

Latest Release
Jul 28, 2025
EPS / Forecast
-0.35 / -0.30
Revenue / Forecast
852.28K / --
EPS Revisions
Last 90 days

GOVX Income Statement

People Also Watch

35.50
BMNR
+3.20%
0.97
KLTO
-1.94%
1.53
WOLF
+0.88%
0.694
WINT
-9.93%
17.29
SRPT
+3.22%

FAQ

What Stock Exchange Does GeoVax Labs Trade On?

GeoVax Labs is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for GeoVax Labs?

The stock symbol for GeoVax Labs is "GOVX."

What Is the GeoVax Labs Market Cap?

As of today, GeoVax Labs market cap is 18.77M.

What Is GeoVax Labs's Earnings Per Share (TTM)?

The GeoVax Labs EPS (TTM) is -2.29.

From a Technical Analysis Perspective, Is GOVX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has GeoVax Labs Stock Split?

GeoVax Labs has split 5 times.

How Many Employees Does GeoVax Labs Have?

GeoVax Labs has 17 employees.

What is the current trading status of GeoVax Labs (GOVX)?

As of 31 Jul 2025, GeoVax Labs (GOVX) is trading at a price of 0.74, with a previous close of 0.77. The stock has fluctuated within a day range of 0.73 to 0.77, while its 52-week range spans from 0.43 to 11.18.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.